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SUPPLEMENTARY NOTES
ABSTRACT:
The purpose of this project is to characterize the breast cancer in women affected with Neurofibromatosis type 1 (NF1) in a multiinstitutional setting. The first aim is to assess the incidence of breast cancer in this cohort and the clinical features of NF1 associated with breast cancer. The second aim is to investigate any characteristic NF1 gene germline mutations in women with breast cancer and to carry out whole exome sequencing to search for other germline mutations. For the third aim, at tumor tissue level, we plan to characterize the selected signaling pathway on archived breast cancer tissue from women with NF1 utilizing immunohistochemistry (IHC) methods. At the somatic level, we plan to study loss of heterozygosity (LOH) of the NF1 gene using ion semiconductor sequencing and MLPA copy number analysis. We also plan to sequence 30 other breast cancer genes on the breast cancer specimens. By the end of May, 2013, a total of 242 cases of NF1 women have been reviewed. Eleven women have had a diagnosis of breast cancer. Statistical analysis was conducted. The presence of plexiform neurofibroma has a trend to be inversely related to the occurrence of breast cancer, however, it has not reached statistical significance (p=0.083). A family history of cancer is associated with a personal history of breast cancer (p=0.000119). No other clinical features or family histories were found to be associated with the occurrence of breast cancer. To date, germline NF1 mutations has been investigated in 10 women with breast cancer. No significant pattern of mutation has been discovered. Nine breast cancer specimens have been collected and are ready to be analyzed. We are expected to review up to 450 cases of women with NF1 and collect another 5 archived breast cancer specimens. The analyses listed in the above aims are to be completed once the final cases have been reviewed and the specimens have been collected. The fourth aim is to study the senescence effects in response to hyper-activated Ras on human mammary epithelial cells (HMEC). The work in year one did not reach any conclusion and HMEC needs a longer period of culture to be tested again. The continuation of this work has just started.
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INTRODUCTION
Several reports from England and United States have described increased breast cancer occurrence in women affected with Neurofibromatosis type 1 (NF1). This study aims at identifying an accurate incidence of breast cancer in this group of women in a multi-center collaborative environment. There are 4 specific aims. Aim 1 is to confirm the increased breast cancer risk in women with NF1. All the participating centers, Henry Ford Health System (HFHS), University of Alabama at Birmingham (UAB), Children's National Medical Center in D.C. (CNMC), and Johns Hopkins University (JHU), will review the medical records of women affected with NF1. Clinical data will be analyzed to determine whether there are clinical features associated with the increased risk for breast cancer. At the same time, women with a history of breast cancer will be recruited to donate blood and their archived tumor specimen. Aim 2 is to analyze the germline NF1 gene and whole exome sequencing in the subjects with history of breast cancer. The NF1 mutations identified will be analyzed for genotype-breast cancer correlation. Other germline gene changes identified may reveal germline breast cancer predisposition in addition to the NF1 gene. Aim 3 is to determine if NF1 associated breast cancers have unique signaling pathways and molecular tumorigenesis characteristics. Immunohistochemistry study of the signaling pathway will be performed on archived tumor blocks. NF1 gene copy number variation will be analyzed on these tumor specimens. Next generation sequencing of a 31 gene panel known to be associated with breast cancer will be performed as well. The NF1 gene is included in the panel. Aim 4 is to study the phenotype of NF1 knockdown in primary mammary epithelial cells. This study will provide information to help in determining when and how to screen for breast cancer in this group of women. It will also shed light on the molecular mechanisms of breast cancer in NF1 deficient human subjects.
BODY
Aim 1:
To confirm the increased breast cancer risk in women with NF1. To identify any clinical features associated with the risk for breast cancer.
Clinical medical history data collection, analysis, patient contact and specimen retrieval
Methods:
Multicenter chart review was performed on 242 women with NF1. Information on common clinical features of NF1, tumor diagnosis, as well as family history of NF1 and cancer diagnosis was collected.
Statistical analysis was performed to detect any association between each clinical feature of NF1 and incidence of cancer. The analyzed features and cancers are illustrated as below.
Clinical features of NF1:
Pigmentary changes on skin and eyes (café au lait spots and Lisch nodules), bony dysplasia, scoliosis, short stature, macrocephaly, learning disability, vasculopathy, cutaneous/dermal neurofibroma, plexiform neurofibroma, optic glioma, and MPNST.
Cancers: Malignant solid tumors, hematological malignancies and central nervous system tumors were classified as "cancer" in this study. Plexiform neurofibroma, cutaneous neurofibroma and schwannoma were not included in the "cancer" category in this report. 
Data:
Aim 2:
To analyze germline NF1 gene on the subjects with history of breast cancer. The mutations identified will be analyzed for genotype-phenotype correlation.
NF1 gene mutation testing and mutation data analysis.
A total of 10 participants who has had a clinical diagnosis of NF1 and breast cancer underwent germline NF1 gene analysis: Table 5 .
Types of NF1 mutation found in 10 women who developed breast cancer. A total of 9 tumor blocks have been collected. Since we are expecting more tumors to be collected, analysis has not been started.
Type of mutation
Tumor specimen molecular analysis by LOH and methylation assay for NF1, p53, BRCA1, BRCA2, PTEN, and ATM genes and IHC assay for proteins, pMEK, ERK, pERK, AKT, mTOR, p53, PTEN, Her2, Ki67 proteins .(Up to 50 specimens and 100 controls) To be completed
Full gene sequencing on formalin-fixed paraffin-embedded (FFPE) tissue: NF1, BRCA1, BRCA2, TP53, PTEN, and ATM genes, and additional breast cancer gene targets including; CDH1, RB1, MLL3, MAP3K1, CDKN1B, PIK3CA, AKT1, GATA3 TBX3, RUNX1, CBFB, AFF2, PIK3R1, PTPN22, PTPRD, 3F3B1, and CCND.
To be completed
Aim 4: Phenotypic Analysis of NF1 knockdown in normal mammary epithelial cells. Mammary cell line (MCF10A) and Human mammary epithelial cells (HMEC) siRNA NF1 lentivirus knockdown construction and phenotype testing -initially was only budgeted for 1 year (month 1-12). The continuation of the project has just started.
To be completed
